UCB Receives “Complete Response” Letter For Cimzia
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says FDA seeks new information and clarification regarding the BLA.
You may also be interested in...
UCB Wins FDA Nod For Cimzia In Crohn’s
Application is pending in rheumatoid arthritis, too.
UCB Wins FDA Nod For Cimzia In Crohn’s
Application is pending in rheumatoid arthritis, too.
EU Committee Upholds Negative Opinions On Cimzia, Rhucin Applications
Pharming will use new Rhucin trial data to support BLA, European appeal.